Nanotherapeutic Solutions for Cardiovascular Disease

per Cooke, John P., Atkins, Johnique
Publicat a Methodist Debakey Cardiovasc J (2016)

Multiple gene aberrations and breast cancer: lessons from super-responders

per Wheler, Jennifer J., Atkins, Johnique T., Janku, Filip, Moulder, Stacy L., Yelensky, Roman, Stephens, Philip J., Kurzrock, Razelle
Publicat a BMC Cancer (2015)

Biomarker-Directed Therapy of Squamous Carcinomas of the Head and Neck: Targeting PI3K/PTEN/mTOR Pathway

per Holsinger, Floyd Christopher, Piha-Paul, Sarina Anne, Janku, Filip, Hong, David S., Atkins, Johnique T., Tsimberidou, Apostolia M., Kurzrock, Razelle
Publicat a J Clin Oncol (2013)

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

per Atkins, Johnique T., George, Goldy C., Hess, Kenneth, Marcelo-Lewis, Kathrina L., Yuan, Ying, Borthakur, Gautam, Khozin, Sean, LoRusso, Patricia, Hong, David S.
Publicat a Br J Cancer (2020)

Innovative Strategies for Decreasing Blood Collection Wait Times for Patients in Early-Phase Cancer Clinical Trials

per Mengistu, Bayabel, Ray, Dina, Lockett, Passion, Dorsey, Vivian, Phipps, Ron A., Subramanian, Harihara, Atkins, Johnique T., El Osta, Badi, Falchook, Gerald S., Karp, Daniel D.
Publicat a J Oncol Pract (2016)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

per Wheler, Jennifer J., Atkins, Johnique T., Janku, Filip, Moulder, Stacy L., Stephens, Philip J., Yelensky, Roman, Valero, Vicente, Miller, Vincent, Kurzrock, Razelle, Meric-Bernstam, Funda
Publicat a Oncoscience (2016)

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

per Wheler, Jennifer J., Moulder, Stacy L., Naing, Aung, Janku, Filip, Piha-Paul, Sarina A., Falchook, Gerald S., Zinner, Ralph, Tsimberidou, Apostolia M., Fu, Siqing, Hong, David S., Atkins, Johnique T., Yelensky, Roman, Stephens, Philip J., Kurzrock, Razelle
Publicat 2014

Phase I Study of Anti-VEGF Monoclonal Antibody Bevacizumab and Histone Deacetylase Inhibitor Valproic Acid in Patients with Advanced Cancers

per Wheler, Jennifer J., Janku, Filip, Falchook, Gerald S., Jackson, Tiffiny L., Fu, Siqing, Naing, Aung, Tsimberidou, Apostalia M., Moulder, Stacy L., Hong, David S., Yang, Hui, Piha-Paul, Sarina A., Atkins, Johnique T., Garcia-Manero, Guillermo, Kurzrock, Razelle
Publicat 2014

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms

per Wheler, Jennifer J., Parker, Barbara A., Lee, Jack J., Atkins, Johnique T., Janku, Filip, Tsimberidou, Apostolia M., Zinner, Ralph, Subbiah, Vivek, Fu, Siqing, Schwab, Richard, Moulder, Stacy, Valero, Vicente, Schwaederle, Maria, Yelensky, Roman, Miller, Vincent A., Stephens, M Philip J., Meric-Bernstam, Funda, Kurzrock, Razelle
Publicat 2014

Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF(V600E) mutation

per Hong, David S., Morris, Van K., Osta, Badi El, Sorokin, Alexey V., Janku, Filip, Fu, Siqing, Overman, Michael J., Piha-Paul, Sarina, Subbiah, Vivek, Kee, Bryan, Tsimberidou, Apostolia, Fogelman, David, Bellido, Jorge, Shureiqi, Imad, Huang, Helen, Atkins, Johnique, Tarcic, Gabi, Sommer, Nicolas, Lanman, Richard, Meric-Bernstam, Funda, Kopetz, Scott
Publicat a Cancer Discov (2016)